on this page
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with mepolizumab under the National Health Act 1953, section 100 for patients with CRSwNP.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing mepolizumab.
Section 100 arrangements
Mepolizumab
This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:
- an approved private hospital
- a public hospital.
This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.
Treatment specifics
To be eligible for PBS-subsidised treatment with mepolizumab, patients must be treated by one or more of the following:
- respiratory physician
- clinical immunologist
- allergist
- ear nose and throat specialist
- general physician with expertise in managing CRSwNP.
Authority applications
Applying for initial treatment
Please note: You don’t need to complete this application in writing when you request PBS authority online.
Applications for initial authority approval to prescribe PBS-subsidised mepolizumab to treat CRSwNP can be made:
- using the Online PBS Authorities system
- in writing and use HPOS Form upload
- in writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed chronic rhinosinusitis with nasal polyps - mepolizumab - initial authority application form
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised mepolizumab to treat CRSwNP can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.